Our elite team has revolutionized antibody discovery. We are the true end-to-end
antibody discovery CRO operating from lead characterization, optimization, engineering and in vivo
analyses, delivering superior products. We succeed because we have the expertise and experience to provide high-throughput
services across the full antibody discovery value chain.
Our next generation of antibody discovery was developed to deliver the most therapeutically relevant
antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. We
offer proprietary antibody discovery technologies, driven by rigorous computational analyses, feeding our B
cell Select™, phage display, and hybridoma generation using semi-solid media and clone picking, to
deliver high affinity antibodies. We have the experience with alternative species or strains, including
transgenic animals or knock-out strains, and
use our Abthena™ bispecific antibody platform to develop products for your therapeutic pipeline.
Antibodies are also critical tools for the diagnosis of disease. Antibodies recognizing unique antigenic
determinants on pathogens, biomarkers, or even an antibody itself (anti-idiotypic) can be developed in
In many research areas, the specificity of the antibody binding is highly important–if not critical-for
the progress of the research.
At ImmunoPrecise, we offer multiple immunization technologies to deliver poly- or monoclonal antibodies
from multi-species, tested in your intended application and delivered in qualities and quantities of your
We pride ourselves on our high customer satisfaction, and our clients have grown accustomed to receiving
very thorough and professional services, with a fast turnaround time. We customize programs to generate
antibodies that meet each of our clients’ specifications.
B cell Select™
Supported by decades of experience, ImmunoPrecise Antibodies’ B-Cell Select™ platform allows for the
interrogation of a greater diversity of an animal’s antibody repertoire than otherwise possible. This
proprietary platform is species independent, allowing for the generation of antibodies from samples not
possible using other methods. B-Cell Select™, which can develop antibodies from any species (including
human) and from any tissue, explores the entire antibody repertoire, and identifies antibodies for anything
that is possible in an animal’s immune repertoire including any protein class, complex therapeutic targets,
post-translational modifications, and small molecules.
The B-Cell Select platform enables the interrogation of ten million blood cells to generate native, monoclonal
antibodies from immunized animals that specifically target an antigen and allow for the rapid selection of top
candidates, drastically increasing the success rate of an antibody discovery program. The platform also
harnesses the power of the immune system to generate natural pairing of the antibodies produced by selected
Our proprietary bispecific Abthena™ technology complements our diverse discovery process,
integrating seamlessly with our Artemis™ Intelligence Metadata (AIM)™ capabilities, to enable
rapid turnaround on additional algorithmic outputs in therapeutic antibody optimization, stability,
affinity, and manufacturability.
We have designed an advanced discovery platform for wild-type and fully human bispecific antibody
components, which allows for the generation of heterodimer, optimized, IgG backbones with validated binding
attributes. Abthena™ produces yields comparable to its monospecific equivalents, with a high degree
of dimer formation.
Our phage display approach is based on building custom immune libraries from multiple species, including
transgenic animals, or the
selection of antigen-specific recombinant antibody fragments from our proprietary human or llama phage
libraries. Our proprietary libraries have been made from human patient and naïve (scFv) repertoires, as well
as from naïve llama (VHH) repertoires. Custom immune libraries are prepared from blood, spleen, lymph nodes,
and bone marrow of immunized animals or humans and capture the entire immune repertoire for panning, rescue,
and identification of unique antibodies with pre-specified characteristics.
We are a full-service, therapeutic antibody discovery company focused on the next generation of antibody
discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the
highest probability of succeeding to clinical trials. The use of transgenic animals producing fully human
idiotypes eliminates the need for a humanization step in the race for a cure. At ImmunoPrecise we successfully
apply the transgenic animal of our client’s choice to our hybridoma, B cell Select™ and
As leaders in hybridoma development, ImmunoPrecise offers cutting edge antibody development services
including, Rapid Prime immunization, DNA immunization (NonaVac™), cell-based immunization
(ModiVacc™), electro-fusion and hybridoma generation using semi-solid media and clone picking, as
well as high throughput, multiplexed screening methods. With ImmunoProtect™, the DNA sequence of your
antibody will be determined and can be used to express your antibody recombinantly.
Animal-derived monoclonal antibodies can elicit human anti-animal antibody responses in patients.
Therefore, it is usually necessary to replace the animal content with the corresponding human amino acid
residues. We provide a robust and efficient antibody humanization service, which consistently retains
affinity and specificity levels. Our approach is based on state of the art in silico antibody modeling using
our Artemis™ Intelligence Metadata (AIM)™ capabilities to identify essential framework and CDR
residues for grafting onto a human antibody framework.